ASA

ISC 2026: Investigational neuroprotective agent boosts recovery after stroke

February 10, 2026

Loberamisal significantly improved functional recovery in patients with acute ischemic stroke in the phase 3 LAIS trial (NCT06517173) presented at ISC 2026. This multicenter, randomized, double-blind study enrolled 998 adults (baseline National Institutes of Health Stroke Scale [NIHSS] 7–20) treated within 48 hours of symptom onset at 32 centers in China. Patients received IV loberamisal 40 mg or placebo once daily for 10 days. At 90 days, 68.1% of patients receiving loberamisal achieved an excellent outcome (modified Rankin Scale [mRS] 0–1) vs. 54.9% with placebo (adjusted risk ratio, 1.24; 95% confidence interval, 1.12–1.37). A prespecified sliding dichotomy analysis also favored loberamisal. Serious adverse events and mortality were similar between groups.

Sources:

Li S, et al. Loberamisal for Acute Ischaemic Stroke (LAIS): A multicenter, randomized, double-blind, parallel, placebo-controlled phase 3 clinical trial. Presented at International Stroke Conference 2026. https://eppro02.ativ.me//web/index.php?page=Session&project=ISC26&id=4447831

(2026, February 6). American Stroke Association. Started within 48 hours of stroke, neuroprotective medication helped brain cells, recovery [News release]. https://newsroom.heart.org/news/started-within-48-hours-of-stroke-neuroprotective-medication-helped-brain-cells-recovery